secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2026-08-28T21:11:48+00:00
Accession:  0001104659-26-103316
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Oncology enters ATM offering to sell up to $50M of common stock
-----------------------------------------------------------------------

- Sales agreement dated Aug 28, 2026 with Leerink Partners LLC for at-the-market sales of common stock.
- Company may offer up to $50.0M aggregate gross proceeds; no obligation to sell any shares.
- Agent commission up to 3% of gross proceeds; customary indemnification provided.
- Proceeds intended for general corporate purposes including working capital.
- Offered under S-3 shelf (effective Dec 8, 2025) with prospectus supplement filed Aug 28, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926103316/0001104659-26-103316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926103316/chrs-20260828x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-103316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer